Lv1
50 积分 2022-12-21 加入
Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies
22天前
已完结
"The RAS Dam Has Broken"
2个月前
已关闭
Discovery of 2-Pyrazolylpyrimidinone Derivatives as New SPOP Inhibitors for Renal Cell Carcinoma Therapy
6个月前
已完结
"Undruggable KRAS": druggable after all
6个月前
已完结
Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies
7个月前
已完结
Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies
7个月前
已完结
Navigating the complexities of pancreatic ductal adenocarcinoma: A review on therapeutic models and RAS inhibitors
8个月前
已关闭
Comparative genomic landscape of acquired resistance in pancreatic cancer treated with pan-RAS or KRASG12C inhibitors
8个月前
已关闭
Response and Resistance to RAS Inhibition in Cancer
8个月前
已完结
Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study
9个月前
已完结
皖公网安备34019202002308
